ArticlePharmaceuticals (Basel, Switzerland)2018
Synthesis and Initial In Vivo Evaluation of [
Article in Pharmaceuticals (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Nuclear Medicine Tracers Targeting Tumor-Associated Macrophages.Pharmaceutics · 2026Review
- CSF1R inhibitor C19 for glioma immunotherapy enabled by brain-targeting liposomal delivery.Acta pharmacologica Sinica · 2026Article
- Fluorine-18-labeled PET radiotracers for imaging the macrophage colony-stimulating factor 1 receptor (CSF1R).EJNMMI radiopharmacy and chemistry · 2026Article
- Evaluation of [Molecular imaging and biology · 2025Article
- The development status of PET radiotracers for evaluating neuroinflammation.Nuclear medicine and molecular imaging · 2024Review
- Fully automated radiosynthesis of [American journal of nuclear medicine and molecular imaging · 2024Article
- Automated radiosynthesis of [American journal of nuclear medicine and molecular imaging · 2024Article
- Candidate Tracers for Imaging Colony-Stimulating Factor 1 Receptor in Neuroinflammation with Positron Emission Tomography: Issues and Progress.ACS pharmacology & translational science · 2023Review
- Development and Optimization ofACS pharmacology & translational science · 2023Review
- PET Imaging of Fructose Metabolism in a Rodent Model of Neuroinflammation with 6-[Molecules (Basel, Switzerland) · 2022Article
- First-in-human use ofEJNMMI research · 2022Article
- Potential PET tracers for imaging of tumor-associated macrophages.EJNMMI radiopharmacy and chemistry · 2022Review
- Synthesis and Evaluation of aPharmaceuticals (Basel, Switzerland) · 2022Article
- The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO.Journal of medicinal chemistry · 2021Review
- Towards PET imaging of the dynamic phenotypes of microglia.Clinical and experimental immunology · 2021Review
- Article
- Neuroinflammation PET Imaging: Current Opinion and Future Directions.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Review
- Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease.Frontiers in aging neuroscience · 2020Review
- BLZ945 derivatives for PET imaging of colony stimulating factor-1 receptors in the brain.Nuclear medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Positron emission tomography (PET) imaging of Colony Stimulating Factor 1 Receptor (CSF1R) is a new strategy for quantifying both neuroinflammation and inflammation in the periphery since CSF1R is expressed on microglia and macrophages. AZ683 has high affinity for CSF1R (K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.